Novartis’ MS drug trumps Sanofi’s Aubagio

16th September 2019 Uncategorised 0

The drug was able to reduce annualised MS relapse rates by 50.5% and 58.5% in the ASCLEPIOS I and II trials.

More: Novartis’ MS drug trumps Sanofi’s Aubagio
Source: News